These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 24127687

  • 1. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R, Chen D, Edwards J, Mathews M.
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [Abstract] [Full Text] [Related]

  • 2. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME.
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR.
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [Abstract] [Full Text] [Related]

  • 4. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
    Clayton AH, Kennedy SH, Edwards JB, Gallipoli S, Reed CR.
    J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
    [Abstract] [Full Text] [Related]

  • 5. Vilazodone: in major depressive disorder.
    Frampton JE.
    CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M.
    J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
    [Abstract] [Full Text] [Related]

  • 7. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR.
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Mathews M, Gommoll C, Chen D, Nunez R, Khan A.
    Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
    [Abstract] [Full Text] [Related]

  • 9. Vilazodone for the treatment of depression.
    Lindsey WT.
    Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
    [Abstract] [Full Text] [Related]

  • 10. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
    Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR.
    J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
    [Abstract] [Full Text] [Related]

  • 11. Vilazodone: a novel antidepressant.
    Choi E, Zmarlicka M, Ehret MJ.
    Am J Health Syst Pharm; 2012 Sep 15; 69(18):1551-7. PubMed ID: 22935937
    [Abstract] [Full Text] [Related]

  • 12. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2012 Apr 15; 66(4):356-68. PubMed ID: 22284853
    [Abstract] [Full Text] [Related]

  • 13. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
    Khan A, Sambunaris A, Edwards J, Ruth A, Robinson DS.
    Int Clin Psychopharmacol; 2014 Mar 15; 29(2):86-92. PubMed ID: 24247740
    [Abstract] [Full Text] [Related]

  • 14. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
    Citrome L, Gommoll CP, Tang X, Nunez R, Mathews M.
    Int Clin Psychopharmacol; 2015 Mar 15; 30(2):75-81. PubMed ID: 25396353
    [Abstract] [Full Text] [Related]

  • 15. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
    Guay DR.
    Consult Pharm; 2012 Dec 15; 27(12):857-67. PubMed ID: 23229074
    [Abstract] [Full Text] [Related]

  • 16. Vilazodone (Viibryd)--a new antidepressant.
    Med Lett Drugs Ther; 2011 Jul 11; 53(1368):53-4. PubMed ID: 21738107
    [Abstract] [Full Text] [Related]

  • 17. Vilazodone for the treatment of major depressive disorder.
    Iranikhah M, Wensel TM, Thomason AR.
    Pharmacotherapy; 2012 Oct 11; 32(10):958-65. PubMed ID: 23033234
    [Abstract] [Full Text] [Related]

  • 18. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
    Khan A.
    Expert Opin Investig Drugs; 2009 Nov 11; 18(11):1753-64. PubMed ID: 19764890
    [Abstract] [Full Text] [Related]

  • 19. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.
    Kornstein S, Chang CT, Gommoll CP, Edwards J.
    Int Clin Psychopharmacol; 2018 Jul 11; 33(4):217-223. PubMed ID: 29608461
    [Abstract] [Full Text] [Related]

  • 20. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.
    Clayton AH, Gommoll C, Chen D, Nunez R, Mathews M.
    Int Clin Psychopharmacol; 2015 Jul 11; 30(4):216-23. PubMed ID: 26039688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.